We advise investors and funds on investing in therapeutic start-ups in Series A and navigating the rapidly evolving legal, regulatory, and pharmacological landscape of psychedelics and psychoplastogens.

Our expertise is built on years of high-level academic work, including extensive collaboration with Nobel Laureate Paul Greengard and his team on various molecular architectures involved in neuroplasticity—the key target of psychedelics. We have also authored numerous scientific publications in Nature, the Journal of Biological Chemistry, the Journal of Neuroscience, and other esteemed journals.

On January 13, 2025, Alexandre Stipanovich was a guest speaker on the GLG Expert Network, discussing Psychedelics for Mental Health (Industry Primer).

Resumes, transcripts of public appearances, and publications are available upon request at alex@cascades-analytics.com.